Cyanamide-associated alcoholic liver disease: a sequential histological evaluation.
This is the first study that we are aware of that followed the histopathological progression of the liver disease that was caused by the combination of both chronic alcohol use and cyanamide, an antidipsotropic agent. Two sequential liver biopsy specimens were obtained on 29 alcoholics who relapsed with varying histories of cyanamide treatment. Cyanamide induced ground-glass inclusions (GGIs) in the hepatocytes. Two groups were identified, depending on whether GGIs proliferated or regressed, which was, in turn, found contingent on the duration of cyanamide treatment and the drug-free period. Group 1 included 14 cases in which GGIs either emerged only in the second biopsy specimen or else were increased in the second specimen as compared in the initial specimen. Group 2 composed of 15 cases in which GGIs were either not observed in either specimen or decreased in the second specimen as compared in the initial specimen. Acidophilic bodies were sequentially increased in five cases (36%) of group 1 and in none of group 2. The severity of portal inflammation worsened in 10 cases (71%) of group 1 but in 2 cases (13%) of group 2, although the changes in fibrotic process did not differ between two groups. These differences could not be explained on the basis of the daily ethanol consumption and the length of relapses of the two groups. Thus, when cyanamide-treated alcoholics relapsed, the combined effect of cyanamide and alcohol produced the development of acidophilic bodies and portal inflammation along with the emergence of GGIs.
Yokoyama
A
A
National Institute on Alcoholism, Kurihama National Hospital, Kanagawa, Japan.
Sato
S
S
Maruyama
K
K
Nakano
M
M
Takahashi
H
H
Okuyama
K
K
Takagi
S
S
Takagi
T
T
Yokoyama
T
T
Hayashida
M
M
D000328:Adult; D000427:Alcohol Deterrents / Q000009:adverse effects* / Q000627:therapeutic use; D000437:Alcoholism / Q000473:pathology / Q000534:rehabilitation*; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D003484:Cyanamide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006519:Hepatitis, Alcoholic / Q000473:pathology; D006801:Humans; D002479:Inclusion Bodies / Q000473:pathology; D007564:Japan; D008099:Liver / Q000473:pathology*; D008104:Liver Cirrhosis, Alcoholic / Q000473:pathology; D008108:Liver Diseases, Alcoholic / Q000473:pathology*; D008297:Male; D008875:Middle Aged
D000427:Alcohol Deterrents; D003484:Cyanamide